CD4 and cancer: The observation that infusion of ex vivo expanded CD4+ T cells that recognized a neo-epitope derived from the mutated ERBB2IP, a gene encoding the ERBB2 interacting protein, into a patient with metastatic cholangio-sarcoma-induced significant tumor regression supports the importance of CD4+ T cells during the anti-cancer immune response [53].